Perspective Therapeutics Provides Business Updates and Strategic Priorities Ahead of Presentation at 43rd Annual J.P. Morgan Healthcare Conference

Core Insights - Perspective Therapeutics is focusing on advancing its clinical pipeline and expanding its manufacturing capabilities over the next 12-18 months [2][6][18] Clinical Pipeline Advancements - The company is conducting a multi-center open-label dose escalation study of [212Pb]VMT-α-NET for patients with unresectable or metastatic SSTR2-positive neuroendocrine tumors [3] - Initial results from the study indicated no dose-limiting toxicities and two grade 3 adverse events, with eight of nine patients showing durable disease control [5][8][16] - The VMT01 program is also in a dose escalation study for previously treated melanoma patients, with initial results presented at a recent conference [9][10] Financial Position - As of December 31, 2024, the company reported preliminary unaudited cash, cash equivalents, and short-term investments of approximately $227.8 million, expected to fund operations into late 2026 [6][14][15] Manufacturing and Infrastructure - The company is working on expanding its manufacturing capabilities by improving existing facilities and evaluating additional capacity expansion opportunities [6][22] - Plans include building out recently acquired sites to enhance the availability of its medicines [6][22] Upcoming Events - The company will present updates at the 43rd Annual J.P. Morgan Healthcare Conference on January 15, 2025 [17]